Mission Statement, Vision, & Core Values (2026) of Torii Pharmaceutical Co., Ltd.

From its founding in 1921 to more than a century of specialization in dermatology, allergology and renal disease, Torii Pharmaceutical Co., Ltd. - headquartered in Tokyo and employing 654 people as of June 30, 2025 - has built a patient-focused legacy that now enters a new chapter after joining the SHIONOGI Group in September 2025; this profile unpacks how Torii's mission to "sincerely serve patients, their families, and those involved in medical care," its long-standing emphasis on sincerity and commitment, and its TORII's POLICY-"Treasure all human connections," shared responsibility, fearless innovation and learning from past experience-drive the company's medium- and long-term blueprint VISION2030, which targets net sales to break the prior record of ¥64.1 billion and operating income to approach the all-time high of ¥13.3 billion, all while balancing obligations to customers, shareholders, society and employees under the 4S MODEL-discover the concrete strategies, in‑licensing focus and cultural pillars that aim to translate these figures into measurable patient impact

Torii Pharmaceutical Co., Ltd. (4551.T) - Intro

Torii Pharmaceutical Co., Ltd., established in 1921 and headquartered in Tokyo, is a specialized Japanese pharmaceutical company focused on development, manufacturing, and marketing of products in dermatology (skin diseases), allergy, and renal disease areas. With a corporate heritage spanning over 100 years, Torii has cultivated long-standing relationships with medical professionals and built a portfolio of niche, high-quality therapeutics. In September 2025, Torii joined the SHIONOGI Group, aligning with a partner that shares its patient-centric values.

• Founded: 1921 (Tokyo headquarters)
• Primary therapeutic focuses: skin diseases, allergens, renal diseases
• Employees: 654 (as of June 30, 2025)
• Group affiliation: Member of the SHIONOGI Group since September 2025
• Centuries-spanning relationships with clinicians and specialty pharmacies

Mission

• Contribute to society by delivering superior health solutions that address unmet medical needs.
• Place patients at the center of decision-making, prioritizing safety, efficacy, and accessibility.
• Maintain rigorous quality standards across research, manufacturing, and distribution.

Vision

• Be a trusted specialist in targeted therapeutic areas, leveraging deep clinical relationships to bring differentiated treatments to market.
• Integrate with partners in the healthcare ecosystem to scale impact and accelerate patient access.
• Continue sustainable growth while preserving a legacy of clinical trust formed over a century.

Core Values

• Patient-first: clinical benefit and patient safety guide strategic choices.
• Scientific rigor: evidence-driven development and quality manufacturing.
• Collaboration: long-term partnerships with clinicians, researchers, and corporate allies.
• Integrity: ethical conduct in clinical practice, regulatory compliance, and commercial activities.
• Continuous improvement: investing in expertise and processes to meet evolving medical needs.

For a detailed corporate history, ownership breakdown, and expanded mission context, see: Torii Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Torii Pharmaceutical Co., Ltd. (4551.T) - Overview

Torii Pharmaceutical Co., Ltd. (4551.T) grounds its corporate identity in a clear, patient-centered mission and a long-term vision shaped by experience, sincerity, and adaptive innovation. The company's guiding statements emphasize service to patients and medical communities, continuous contribution to health and quality of life, and a commitment to evolve while preserving trust earned over a long history.

• Purpose: 'Sincerely serve patients, their families, and those involved in medical care.'
• Health contribution: 'Contribute to the healthy recovery of patients, as well as to a happy, enriched life free from fear of illness.'
• Adaptability: 'Flexibly change and adapt to meet the needs of the times and the environment, while retaining the trust we have earned over our long history.'
• Unique contribution: 'Continue to take on the challenge of contributing to healthcare that only we can make.'
• Values: Emphasis on 'sincerity and commitment' as the company's finest qualities.
• Learning from history: 'All of our past experiences fuel our continued growth.'

These principles translate into measurable strategic priorities across R&D, manufacturing, regulatory compliance, and market expansion. The following table summarizes key corporate metrics and recent financial/operational indicators to show how mission and values map to performance and resource allocation.

Core values and strategic actions align closely:

• Sincerity & commitment - demonstrated by patient-focused product development and post-market surveillance processes.
• Adaptability - evidenced by licensing partnerships, selective international distribution, and responsive manufacturing shifts during demand changes.
• Learning from history - continual quality improvements and incremental innovation built on legacy formulations and clinical experience.

Operationally, Torii translates mission into measurable programs:

• R&D pipeline management that prioritizes therapeutic areas with clear patient benefit and unmet need.
• Quality assurance investments to maintain regulatory compliance domestically and for exporting partners.
• Stakeholder engagement initiatives aimed at patients, healthcare professionals, and caregivers to uphold trust and gather real-world feedback.

For investors and stakeholders seeking an in-depth financial analysis that connects these mission-driven priorities to balance sheet and market performance, see: Breaking Down Torii Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors

Torii Pharmaceutical Co., Ltd. (4551.T) - Mission Statement

• Commit to patient-centered drug development and commercialization that address unmet medical needs.
• Strengthen in-licensing activities to accelerate access to innovative assets and technologies.
• Build flexible organizational and commercial frameworks to adapt to changing medical, regulatory, and market environments.
• Preserve financial discipline while investing to capture upside from product value maximization.

VISION2030 - Medium-/Long-Term Business Vision

• Numerical ambition: surpass previous company bests - net sales > ¥64.1B and operating income approaching/exceeding ¥13.3B by 2030.
• Execution levers: vigorous in-licensing pipeline, commercialization optimization, lifecycle management to extract maximum product value.
• Organizational principle: 'flexibly change and adapt to meet the needs of the times and the environment.'

How the Mission and Vision Translate into Action

• In-licensing: prioritize transactions that fast-track access to late-stage or differentiated assets to enhance near- and medium-term revenue streams.
• Value maximization: implement pricing, indication expansion, and distribution strategies designed to extend product lifetime value.
• Adaptive organization: invest in cross-functional capabilities (regulatory, market access, digital commercialization) to respond rapidly to market shifts.
• Patient impact: align pipeline and partnered portfolios toward therapies with clear clinical benefit and measurable improvements in patient quality of life.

Torii Pharmaceutical Co., Ltd. (4551.T) - Vision Statement

• Global presence: expand registered products and strategic alliances across Asia, Europe and North America to increase overseas sales share to 30% within five years.
• R&D-driven value: target a pipeline conversion rate (Phase I→Approval) improvement of 20% through focused therapeutic-area investments and external collaborations.
• Financial sustainability: pursue mid-single-digit to high-single-digit annual revenue growth while maintaining an operating margin above industry averages.

Core Values - TORII's POLICY

• Treasure all human connections - prioritize patients, partners and employee relationships in decision-making and partnership selection.
• Sincerity and commitment - maintain ethical conduct, clinical rigor and transparent communication across all stakeholders.
• We all have a stake. We all have a role - promote shared responsibility through cross-functional ownership of outcomes.
• Try new things without fear - encourage controlled experimentation, pilot programs and external co-development to accelerate innovation.
• All of our past experiences fuel our continued growth - capture institutional learning from launches, clinical programs and market access efforts.

4S MODEL - Balancing Stakeholder Responsibilities

• Customers: deliver safe, effective medicines with timely supply and patient support programs.
• Shareholders: create long-term value via profitable growth, dividend policy and capital efficiency.
• Society: contribute to public health through access initiatives, compliance and environmental stewardship.
• Staff: invest in capability-building, diversity and safety to sustain innovation and operational excellence.

How Values Translate into Key Performance Indicators

• Patient-centric KPIs: product-specific adherence programs, patient-reported outcomes and time-to-market for priority drugs.
• Operational KPIs: supply continuity rate (>99%), on-time delivery and manufacturing quality metrics.
• Financial KPIs: revenue growth, operating margin, free cash flow and return on invested capital (ROIC).
• People & culture KPIs: employee engagement score, internal promotion rate and training hours per employee.

Governance and Accountability